<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82307">
  <stage>Registered</stage>
  <submitdate>27/09/2007</submitdate>
  <approvaldate>5/10/2007</approvaldate>
  <actrnumber>ACTRN12607000510448</actrnumber>
  <trial_identification>
    <studytitle>Biomarker evaluation of short-term administration of chemotherapeutic or biologic agents in patients with unresectable Stage IV melanoma amenable to pre- and post-treatment biopsy.</studytitle>
    <scientifictitle>Biomarker evaluation of short-term administration of chemotherapeutic or biologic agents in patients with unresectable Stage IV melanoma amenable to pre- and post-treatment biopsy.</scientifictitle>
    <utrn />
    <trialacronym>TEAM - SMN 0107</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Biopsies of in transit lesions (x2 mandatory 1 pre treatment and the other 7 days post treatment) and up to 4 optional biopsies possible at 14, 21, 28 &amp; 56 days post treatment
Bloods will be collected at the following intervals: Baseline = Full Blood Count (FBC), Electrolytes, Urea &amp; Creatinine (EUC), Liver Function Tests (LFTs), Lactate Dehydrogenase (LDH), International Normalised Ratio (INR), Activated Partial Thromboplastin Time (APTT), serum storage, flow cytometry &amp; Deoxyribonucleic acid (DNA) &amp; Ribonucleic acid (RNA) extraction
Days 7, 14 &amp; 21 = FBC, serum storage &amp; flow cytometry
Days 28 &amp; 56 = FBC, serum storage, flow cytometry &amp; DNA/RNA extraction

Expected study duration 18 months</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Other interventions</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine if short-term administration drug therapy produces histological, immunological and molecular changes in melanoma indicative of potential anti-tumour activity. Where present, such changes may assist in the selection of agents for more extensive clinical testing alone and in combination with other drugs.</outcome>
      <timepoint>Biopsies of in transit lesions (x2 mandatory 1 pre treatment and the other 7 days post treatment) and up to 4 optional biopsies possible at 14, 21, 28 &amp; 56 days post treatment
Bloods will be collected at the following intervals: Baseline = Full Blood Count (FBC), Electrolytes, Urea &amp; Creatinine (EUC), Liver Function Tests (LFTs), Lactate Dehydrogenase (LDH), International Normalised Ratio (INR), Activated Partial Thromboplastin Time (APTT), serum storage, flow cytometry &amp; Deoxyribonucleic acid (DNA) &amp; Ribonucleic acid (RNA) extraction
Days 7, 14 &amp; 21 = FBC, serum storage &amp; flow cytometry
Days 28 &amp; 56 = FBC, serum storage, flow cytometry &amp; DNA/RNA extraction</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To correlate these changes in tumour biopsies with effects on circulating immunological and haematological parameters.</outcome>
      <timepoint>Biopsies of in transit lesions (x2 mandatory 1 pre treatment and the other 7 days post treatment) and up to 4 optional biopsies possible at 14, 21, 28 &amp; 56 days post treatment
Bloods will be collected at the following intervals: Baseline = Full Blood Count (FBC), Electrolytes, Urea &amp; Creatinine (EUC), Liver Function Tests (LFTs), Lactate Dehydrogenase (LDH), International Normalised Ratio (INR), Activated Partial Thromboplastin Time (APTT), serum storage, flow cytometry &amp; Deoxyribonucleic acid (DNA) &amp; Ribonucleic acid (RNA) extraction
Days 7, 14 &amp; 21 = FBC, serum storage &amp; flow cytometry
Days 28 &amp; 56 = FBC, serum storage, flow cytometry &amp; DNA/RNA extraction</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To correlate these changes in tumour biopsies with tumour response.</outcome>
      <timepoint>Biopsies of in transit lesions (x2 mandatory 1 pre treatment and the other 7 days post treatment) and up to 4 optional biopsies possible at 14, 21, 28 &amp; 56 days post treatment
Bloods will be collected at the following intervals: Baseline = Full Blood Count (FBC), Electrolytes, Urea &amp; Creatinine (EUC), Liver Function Tests (LFTs), Lactate Dehydrogenase (LDH), International Normalised Ratio (INR), Activated Partial Thromboplastin Time (APTT), serum storage, flow cytometry &amp; Deoxyribonucleic acid (DNA) &amp; Ribonucleic acid (RNA) extraction
Days 7, 14 &amp; 21 = FBC, serum storage &amp; flow cytometry
Days 28 &amp; 56 = FBC, serum storage, flow cytometry &amp; DNA/RNA extraction</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Where possible, to correlate these changes with biological effects on normal naevus cells from the same patient</outcome>
      <timepoint>Biopsies of in transit lesions (x2 mandatory 1 pre treatment and the other 7 days post treatment) and up to 4 optional biopsies possible at 14, 21, 28 &amp; 56 days post treatment
Bloods will be collected at the following intervals: Baseline = Full Blood Count (FBC), Electrolytes, Urea &amp; Creatinine (EUC), Liver Function Tests (LFTs), Lactate Dehydrogenase (LDH), International Normalised Ratio (INR), Activated Partial Thromboplastin Time (APTT), serum storage, flow cytometry &amp; Deoxyribonucleic acid (DNA) &amp; Ribonucleic acid (RNA) extraction
Days 7, 14 &amp; 21 = FBC, serum storage &amp; flow cytometry
Days 28 &amp; 56 = FBC, serum storage, flow cytometry &amp; DNA/RNA extraction</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Life expectancy of at least 2 months; Eastern Cooperative Oncology Group (ECOG) performance status score 0-3; Histologic or cytologic diagnosis of unresectable Stage IV malignant melanoma; Required values for initial laboratory tests: White Blood Count (WBC) = 3000 x 103/mL; Absolute Neutrophil Count (ANC) = 1500 x 103/mL; Platelets = 90 x 106/mL; Haemoglobin = 9 g/dL; Aspartate aminotransferase (AST) = 3 x Upper Limit of normal (ULN) for patients without liver metastasis; = 5 x Upper Limit of normal (ULN) for patients with liver metastasis; Bilirubin = 2 x Upper Limit of normal (ULN), (except patients with Gilberts Syndrome, who must have a total bilirubin less than 3.0 mg/mL); 
Creatinine = 1.5 x Upper Limit of normal (ULN); At least 4 weeks post chemotherapy (at least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin), immunotherapy, hormonal therapy, or major surgery and the beginning of protocol therapy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Metastatic ocular melanoma; Symptomatic, untreated central nervous system (CNS) metastasis; Use of any immunosuppressing treatments including corticosteroids (patients on stable doses of hormone replacement therapy are exempt), cyclosporine, mycophenolate mofetil, chemotherapy, radiation, etc, within 4 weeks prior to Day 1 of treatment; Any other malignancy from which the patient has been disease-free for less than 2 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or Stage I carcinoma of the prostate; Concomitant therapy with any of the following: IL-2, interferon or other non-study anti-melanoma immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids (patients on stable doses of hormone replacement therapy are exempt).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence>Not randomised no sequence required</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2060</postcode>
    <postcode>2050</postcode>
    <postcode>2145</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney South West Area Health Service RPA Hospital</primarysponsorname>
    <primarysponsoraddress>Royal Prince Alfred Hospital
Missenden Rd Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC Grant</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Institute NSW Fellowships x2</fundingname>
      <fundingaddress>Cancer Institute NSW 
PO Box 41 
ALEXANDRIA NSW 1435
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Sydney Westmead Area Health Service Westmead Hospital</sponsorname>
      <sponsoraddress>Westmead Hospital
Hawkesbury Rd Westmead NSW 2145</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Sydney Melanoma Unit</othercollaboratorname>
      <othercollaboratoraddress>1A Eden St
North Sydney
NSW 2060</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>People with melanoma that has spread from the skin to the lymph nodes or internal organs respond differently to chemotherapy drugs. But it often takes several months of chemotherapy to determine if a particular drug is working. The aim of this study is to see whether doing tests on a tumour that has been removed from the body after 1 cycle of chemotherapy can help predict if an individual will benefit from that chemotherapy.</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil to date</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SSWAHS Ethics Committee</ethicname>
      <ethicaddress>Ethics Review Committee (RPAH Zone)
C/- Research Development Office
Level 8, Building 14
Royal Prince Alfred Hospital
Missenden Rd Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>31/07/2007</ethicapprovaldate>
      <hrec>X07-0049</hrec>
      <ethicsubmitdate>1/02/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney West Area Health Service</ethicname>
      <ethicaddress>HREC
Research Office 
Room 2020 Clinical Sciences Building
Westmead Hospital
Hawkesbury Rd
Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate>4/09/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>27/06/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Rick Kefford</name>
      <address>Westmead Milennium Institute
Westmead NSW 2145</address>
      <phone>9845 8089</phone>
      <fax />
      <email>rick_kefford@wmi.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melanie Lean</name>
      <address>1A Eden St
North Sydney
NSW 2060</address>
      <phone>9911 7200</phone>
      <fax>9954 9435</fax>
      <email>Melanie.Lean@smu.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melanie Lean</name>
      <address>1A Eden St
North Sydney
NSW 2060</address>
      <phone>9911 7200</phone>
      <fax>9954 9435</fax>
      <email>Melanie.Lean@smu.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>